Skip navigation

Pharmaceutical and Biotechnology Construction Sector Report - UK 2018-2022

Published: 26/09/2018 / Number of Pages: 99 / Price: £845.00

Order Now

Format Optionsi

A PDF is included in report price, all other options also include a PDF file. For further details on purchase options, please click here.

Licence Optionsi

A single user licence is included in report price, but we offer a range of licences to suit your needs. For further details, please click here.

Total Price: £845.00

Order/Delivery FAQ

Other Questions?

Call us on
01242 235724
Or email us

Download Brochure

Introduction and Overview

The 4th edition of the 'Pharmaceutical & Biotechnology Construction Sector Report - UK 2018-2022' focuses on the market size, value and activity in the Pharmaceutical, Medical Technology, Medical and Industrial Biotechnology sectors in the UK, the key players and geographical areas of manufacturing and R&D concentration.

Key issues covered in the report:

  • Introduction to the biopharmaceutical, medical technology and associated sub-sectors.
  • Market size, value, key players and geographical areas of concentration.
  • Detailed analysis of pharmaceutical clusters and centres of excellence in the UK.
  • Overview of the main manufacturing and R&D facilities in the UK
  • Analysis of Government initiatives, resource and capital funding for science R&D.

Areas of particular interest:

  • Review of the main challenges facing the pharmaceutical sector.
  • Analysis of the potential long-term impact of Brexit on the UK pharmaceutical sector.
  • Review of leading specialist supply companies to the Pharma industry.
  • Major engineering construction companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects.
  • Capital expenditure levels for both pharmaceutical R&D and manufacturing in the UK.
  • Analysis of construction costs/ issues in the design of pharmaceutical R&D and manufacturing facilities.
  • Detailed profiles of the top pharmaceutical and biotechnology companies operating in the UK.

Some of the companies includes:

ABB, AECOM, AMEC Foster Wheeler, Ardmac, BDP, Bilfinger Berger, Bouygues Energies & Services, Cavendish Engineers, Environmental Engineering, ISG, Jacobs, Kier, Laing O'Rourke, M+W, Merit Merrell, Morgan Sindall, PM Group, SDC, Shepherd Construction, John Sisk, Skanska, Willmott Dixon, Wilson Mason and more.


CONSTRUCTION ACTIVITY IN THE UK BIOPHARMACEUTICAL SECTOR

  • Construction market overview - total construction output to 2022.
  • Market size and output - current situation; market prospects; construction pipeline.
  • Capital expenditure in the UK biopharmaceutical sector.
  • UK science parks and university innovation campuses.
  • Enterprise zones - university enterprise zones; catapult centres.
  • Construction issues - construction costs; contamination control issues; clean rooms; containment laboratories.

CONSTRUCTION CAPABILITY AND SUPPLY

  • Overview of the supply chain.
  • Key engineering and construction companies/contractors in the UK biopharmaceutical sector.
  • Value of projects by sub sector.
  • Engineering & construction contractor profiles.
  • Other contractors in the pharmaceutical/biotech sector.
  • Specialist clean room construction, supply and services.

PHARMACEUTICAL INDUSTRY MARKET SIZE AND OVERVIEW

  • Market definition, size and value.
  • Global pharmaceutical market.
  • UK pharmaceutical market - biopharmaceutical sector; medical technology sector; digital health sector; genomics sector.
  • Location of biopharmaceutical manufacturing sites.
  • Pharmaceutical/biotechnology clusters.
  • Future of pharmaceutical manufacturing operations in the UK.
  • Value of pharmaceutical industry to the UK economy - UK trade in pharmaceuticals; sales of drugs to the NHS.
  • Pharmaceutical R&D in the UK - government funding for science R&D; total funding; capital funding.
  • Market drivers and key Issues in the pharmaceutical industry.
  • Implications of Brexit for the UK pharmaceutical sector.

LEADING COMPANIES IN THE SECTOR

  • Pharmaceutical company league tables.
  • Global pharmaceutical companies.
  • Profiles of leading pharmaceutical companies in the UK.
  • Other pharmaceutical/biotechnology SME's - biotechnology - therapeutics/diagnostics; biotechnology/biopharm R&D.

Report Summary

The UK is one of the largest pharmaceutical markets in the world, and the sector makes a greater contribution to the UK economy than any other industrial sector. Pharmaceuticals account for 9% of UK manufacturing output and almost 5% of total exports. Investment activity has been slowly increasing over the last couple of years with confidence beginning to return to the market and this looks set to continue into 2016-17, despite the ongoing threat of global economic uncertainty and the more recent threat of the UK's exit from the EU.

The level of construction output in the pharmaceutical sector has also grown in recent years, with a focus of developments on high-value laboratories / cleanrooms, some of the most expensive types of building to construct, partly due to requirements for extensive ventilation and cooling systems. The industry is expected to continue to show modest growth over the next few years, reflecting the positive growth factors from the growing UK pharmaceutical industry, but constrained by the economic uncertainty created by the UK's vote to leave the EU.

Although the volume of work has increased, tender opportunities are becoming increasingly competitive resulting in tighter margins and, despite renewed activity, many UK pharmaceutical producers are not significantly increasing levels of capital expenditure. Increasing specialisation within the pharmaceutical industry has brought about varied opportunities to design and develop R&D facilities, production processes, and assembly of drug delivery systems, as well as construction and maintenance of highly specialised production facilities and associated service or support facilities.

The Government has announced a forward pipeline of over £1.9bn worth of capital projects in the pharmaceutical and biotechnology sectors between now and 2020. In addition to these confirmed capital projects, a number of expansion plans have been announced by leading pharmaceutical companies, which should be of interest to construction companies and their supply chains operating in the pharmaceutical sector.


List of contents

Contents Listing

  1. 1. INTRODUCTION 7
  2. 1.1 INTRODUCTION 7
  3. 1.2 SOURCES OF INFORMATION 7
  4. 2. SUMMARY AND MARKET PROSPECTS 9
  5. 2.1 SUMMARY 9
  6. 2.2 UK PHARMACEUTICALS SECTOR - MARKET PROSPECTS 11
  7. 3. ECONOMIC ENVIRONMENT 14
  8. 3.1 GDP 14
  9. 3.2 INFLATION & INTEREST RATES 15
  10. 3.3 UNEMPLOYMENT 16
  11. 3.4 HOUSEHOLD CONSUMPTION 16
  12. 3.5 HOUSING & CONSTRUCTION 17
  13. 3.6 STERLING 18
  14. 3.7 POPULATION PROFILE 18
  15. 3.8 CONCLUSIONS 19
  16. 4. CONSTRUCTION ACTIVITY IN THE UK PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS 20
  17. 4.1 NON-RESIDENTIAL CONSTRUCTION OUTPUT 20
  18. 4.1.1 Non-Residential Construction Output by Sector 21
  19. 4.2 DEFINITION - PHARMACEUTICALS AND BIOTECHNOLOGY 23
  20. 4.3 MARKET SIZE - PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE 23
  21. 4.3.1 Current Situation 23
  22. 4.3.2 Market Prospects 24
  23. 4.3.3 Construction Pipeline 25
  24. 4.4 CAPITAL EXPENDITURE IN THE PHARMACEUTICAL SECTOR 28
  25. 4.5 SCIENCE PARKS / UNIVERSITY INNOVATION CAMPUSES 30
  26. 4.6 ENTERPRISE ZONES 33
  27. 4.6.1 University Enterprise Zones 35
  28. 4.6.2 Catapult Centres 35
  29. 4.7 CONSTRUCTION ISSUES IN THE PHARMACEUTICAL INDUSTRY 36
  30. 4.7.1 Construction Costs 36
  31. 4.7.2 Contamination Control Issues 37
  32. 5. CONSTRUCTION CAPABILITY AND SUPPLY CHAIN 40
  33. 5.1 OVERVIEW OF THE SUPPLY CHAIN 40
  34. 5.2 KEY CONSTRUCTION COMPANIES AND CONTRACTORS IN THE PHARMACEUTICAL & BIOTECH SECTOR 40
  35. 5.2.1 Value of Projects by Sub Sector 40
  36. 5.2.2 Engineering & Construction Contractor Profiles 42
  37. 5.3 SPECIALIST CLEAN ROOM CONSTRUCTION, SUPPLY AND SERVICES 50
  38. 6. PHARMACEUTICAL INDUSTRY MARKET SIZE AND OVERVIEW 54
  39. 6.1 MARKET DEFINITION, SIZE AND VALUE 54
  40. 6.1.1 Global Pharmaceutical Market 54
  41. 6.1.2 UK Biopharmaceutical / Life Sciences Market 55
  42. 6.1.3 Location of Biopharmaceutical Manufacturing Sites 56
  43. 6.2 PHARMACEUTICAL/BIOTECHNOLOGY CLUSTERS 60
  44. 6.2.1 Oxford Biotech Cluster 61
  45. 6.2.2 London, Cambridge and Stevenage Biotech Clusters 61
  46. 6.2.3 The North 63
  47. 6.2.4 Scotland 65
  48. 6.2.5 Wales & N. Ireland 65
  49. 6.2.6 Future of Pharmaceutical Manufacturing Operations in the UK 66
  50. 6.3 VALUE OF PHARMACEUTICAL INDUSTRY TO THE UK ECONOMY 67
  51. 6.3.1 UK Trade in Pharmaceuticals 67
  52. 6.4 SALES OF PHARMACEUTICAL DRUGS TO THE NHS 68
  53. 6.5 PHARMACEUTICAL R&D IN THE UK 69
  54. 6.5.1 Government Funding for Science R&D 69
  55. 6.5.2 Pharmaceutical Company Investment in R&D 72
  56. 6.5.3 R&D Pipeline 74
  57. 6.6 MARKET DRIVERS AND KEY ISSUES IN THE PHARMACEUTICAL INDUSTRY 75
  58. 6.6.1 Key General Issues Facing the Pharmaceutical Sector 75
  59. 6.6.2 Implications of Brexit for the UK Pharmaceutical Sector 78
  60. 7. LEADING COMPANIES IN THE PHARMACEUTICAL & BIOTECHNOLOGY SECTORS 82
  61. 7.1 PHARMACEUTICAL COMPANY LEAGUE TABLES 82
  62. 7.1.1 Global 827.1.2 Top Pharmaceutical Companies in the UK 83
  63. 7.2 COMPANY PROFILES 84
  64. 7.2.1 GSK 84
  65. 7.2.2 Johnson & Johnson 85
  66. 7.2.3 Merck KGaA 86
  67. 7.2.4 Teva 87
  68. 7.2.5 Baxter Healthcare 88
  69. 7.2.6 Sanofi 88
  70. 7.2.7 AstraZeneca 89
  71. 7.2.8 Abbott 90
  72. 7.2.9 Novartis 90
  73. 7.2.10 Pfizer 91
  74. 7.2.11 Other Global Pharma Companies in the UK 92
  75. 7.3 OTHER PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES 93
  76. 7.3.1 Biotechnology - Therapeutics/Diagnostics 93
  77. 7.3.2 Biotechnology / Biopharm R&D 94
  78. 7.3.3 Pharmaceutical 95

Tables & Contents

  1. CHART 1: ESTIMATED VALUE OF CONSTRUCTION OUTPUT IN THE PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE (£M AT CURRENT PRICES) 2013-2022 10
  2. TABLE 2: GDP DATA - 2015-2018 - KEY CONSTITUENT ELEMENTS 14
  3. CHART 3: INTEREST RATES AND INFLATION (CPI) FROM 2000-2022 16
  4. CHART 4: PDI & SAVINGS RATIO AT CURRENT PRICES 2000-2022 17
  5. TABLE 5: EXCHANGE RATE FLUCTUATIONS 2014-2020 - STERLING TO THE DOLLAR, AND THE EURO, SPOT RATES 18
  6. CHART 6: VALUE OF NON RESIDENTIAL CONSTRUCTION OUTPUT 2013-2022 BY VALUE (£BN AT CURRENT PRICES) 20
  7. CHART 7: NON-RESIDENTIAL CONSTRUCTION OUTPUT (GB) BY SECTOR 2017 - % BY VALUE 21
  8. CHART 8: ESTIMATED VALUE OF CONSTRUCTION OUTPUT IN THE PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE (£M AT CURRENT PRICES) 2011-2022 23
  9. TABLE 9: UK SCIENCE AND RESEARCH PROJECTS: FORWARD CONSTRUCTION PIPELINE 26
  10. CHART 10: UK PHARMACEUTICAL INDUSTRY CAPITAL EXPENDITURE - R&D AND MANUFACTURING OPERATIONS (£M) 2009 - 2016 29
  11. TABLE 11: UK SCIENCE PARKS - SIZE, GEOGRAPHICAL SPREAD, SECTORS AND KEY PARTNERS 31
  12. TABLE 12: AIRBORNE PARTICULATE CLEANLINESS CLASSES FOR CLEAN ROOMS (BASED ON ISO 14644-1: 2015) 38
  13. CHART 13: UK PHARMACEUTICAL/BIOTECH SECTOR - CONTRACT AWARDS BY SUB SECTOR MAY 2016 TO JUNE 2018 41
  14. CHART 14: GLOBAL PHARMACEUTICAL MARKET BY VALUE (£BN): 2013 - 2022 54
  15. CHART 15: SIZE OF THE UK LIFE SCIENCES SECTOR BY TURNOVER AND NO. COMPANIES 2016-17 (BIOPHARMACEUTICALS AND MEDICAL TECHNOLOGY) (BY % AND VALUE £BN) 55
  16. TABLE 16: DISTRIBUTION OF UK BIOPHARMACEUTICAL SITES (MANUFACTURING AND R&D) BY GEOGRAPHICAL AREA (%) 57
  17. TABLE 17: BIOPHARMACEUTICAL/MEDICAL TECHNOLOGY SECTORS: MAJOR COMPANIES AND GEOGRAPHICAL LOCATION OF FACILITIES IN THE UK 2018 - MANUFACTURING, R&D, AND PACKAGING & LOGISTICS 58
  18. TABLE 18: BIOTECHNOLOGY CLUSTERS - LONDON/SOUTH EAST/EASTERN AREAS BY SIZE AND VALUE (£BN) 60
  19. CHART 19: PHARMACEUTICAL TRADE IN THE UK: 2010 - 2017 BY VALUE (£M) 68
  20. TABLE 20: GOVERNMENT RESEARCH & INNOVATION BUDGET 2017-18 TO 2020-21 (£M) 70
  21. TABLE 21: GOVERNMENT RESEARCH & INNOVATION BUDGET 2017-18 TO 2019-20 BY RESEARCH ORGANISATION (£M) 70
  22. TABLE 22: GOVERNMENT SCIENCE INFRASTRUCTURE BUDGET 2017-18 TO 2019-20 BY RESEARCH ORGANISATION (£M) 71
  23. TABLE 23: TOP 25 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY GLOBAL R&D SPEND 2017 (£BN AND BY % OF RX - PRESCRIPTION SALES) 73
  24. TABLE 24: TOP 20 GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY DRUG PIPELINE SIZE IN 2016 AND 2018 74
  25. TABLE 25: TOP 20 GLOBAL PHARMA COMPANIES BY MARKET SHARE (%) 2017 82
  26. TABLE 26: TOP 20 LIFE SCIENCE COMPANIES IN UK BY NUMBER OF UK MANUFACTURING PLANTS 84
  27. TABLE 27: GSK - KEY UK LOCATIONS 85
  28. TABLE 28: JOHNSON & JOHNSON -KEY UK LOCATIONS 86
  29. TABLE 29: MERCK KGAA -KEY UK LOCATIONS 87
  30. TABLE 30: TEVA -KEY UK LOCATIONS 87TABLE 31: BAXTER HEALTHCARE - KEY UK LOCATIONS 88
  31. TABLE 32: SANOFI - KEY UK LOCATIONS 89
  32. TABLE 33: ASTRAZENECA - KEY UK LOCATIONS 90
  33. TABLE 34: ABBOTT LABORATORIES - KEY UK LOCATIONS 90
  34. TABLE 35: NOVARTIS - KEY UK LOCATIONS 91
  35. TABLE 36: PFIZER- KEY UK LOCATIONS 92

The 'Pharmaceutical and Biotechnology Construction Sector Report - UK 2018-2022' costs £845+VAT (if applicable) for a PDF version.

Other formats are available - click here  for a information about available report formats. All AMA reports are sold with a single user licence as standard. For more information about AMA licences click here .